肺结核还是脱发?重新定位医学研究

普林斯顿 – 理想世界中,我们为治疗某种疾病而花在医学研究上的经费应该是和此病的严重性和受此疾病困扰的人数成比例的。而现实世界中,医学研究的90%的经费集中在仅10%的引起死亡和残疾的全球性疾病上。

换句话说,世界卫生组织称之为“全球疾病负担”的十分之九的疾病仅有世界上十分之一的医疗研究在为之努力。结果是,每年数以百万计的人死于没有新药可治的疾病,而药品公司却投入数十亿的资金来开发治疗勃起功能不良和脱发的药品。

但是,因此而指责制药公司却是过于简单了。制药公司只有在预计到销售该药能赚回成本的前提下,才会考虑开发一种新药。如果这些新药针对的是那些影响富人或生活在有全民健康保险的国家的人的疾病,药厂就能为新发明的药品注册专利。在20年的专利期限中,他们会垄断药品的销售,保证了药品高价。

To continue reading, please log in or enter your email address.

To read this article from our archive, please log in or register now. After entering your email, you'll have access to two free articles from our archive every month. For unlimited access to Project Syndicate, subscribe now.

required

By proceeding, you agree to our Terms of Service and Privacy Policy, which describes the personal data we collect and how we use it.

Log in

http://prosyn.org/nuS7QpK/zh;

Cookies and Privacy

We use cookies to improve your experience on our website. To find out more, read our updated cookie policy and privacy policy.